Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 5/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634157 | 0.81 | GHSR (0.61) | GHSRCCR3TACR1TEAD1KDR | |
| SCHEMBL3634458 | 0.79 | GHSR (0.69) | GHSRTACR1KDRCYP1A2 | |
| SCHEMBL3741445 | 0.78 | GHSR (0.63) | GHSRCCR3TACR1TACR3 | |
| SCHEMBL13044525 | 0.78 | GHSR (0.68) | GHSRCCR3TACR1TACR3 | |
| SCHEMBL3637108 | 0.78 | GHSR (0.62) | GHSRCCR3TACR1KDRTACR3 | |
| SCHEMBL3637124 | 0.78 | GHSR (0.68) | GHSRTACR1TACR3 | |
| SCHEMBL3634225 | 0.77 | GHSR (0.67) | GHSRCCR3TACR1TACR3 | |
| SCHEMBL13044526 | 0.77 | GHSR (0.61) | GHSRTACR1 | |
| SCHEMBL3636800 | 0.77 | GHSR (0.61) | GHSROGATACR1CYP1A2 | |
| SCHEMBL3638762 | 0.76 | NAMPT (0.42) | NAMPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | claimed |
| EP-2167466-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | claimed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | claimed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2167466-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GIPR, GHSR, GLP1R | GHSR 2/4885MCHR1 82/4885RET 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.